stockrowXencor, Inc.
XNCR Healthcare Biotechnology
Xencor, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $125.6 million, up 13.7% from fiscal 2024.
- Revenue
- +17.5%
- EPS
- +29.3%
- Free cash flow
- −52.9%
Quarter to June 2026, against a year earlier
Follow XNCR
Alert me
Xencor, Inc. (XNCR) Operating cash flow
Xencor, Inc.'s operating cash flow for fiscal 2025 was −$135.1M, compared with −$202.2M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$205.8M. Over the past ten years it has ranged from −$202.2M (fiscal 2024) to $95.2M (fiscal 2016); the current reading is higher than 18% of that period. Xencor, Inc. ranks 546th of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | −$135.1M | — |
| FY2024 | −$202.2M | — |
| FY2023 | −$77.9M | — |
| FY2022 | $24.5M | — |
| FY2021 | −$16.9M | — |
| FY2020 | −$5.0M | — |
| FY2019 | $64.4M | — |
| FY2018 | −$79.8M | — |
| FY2017 | −$33.6M | — |
| FY2016 | $95.2M | 257.15% |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Jun 2026 | −$55.7M | — |
| Mar 2026 | −$67.6M | — |
| Dec 2025 | −$51.7M | — |
| Sep 2025 | −$30.8M | — |
| 42 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| ADMA ADMA Biologics Inc compare | $140.8M |
| MBX MBX Biosciences, Inc. compare | −$82.7M |
| NAMS NewAmsterdam Pharma Company N.V. compare | −$150.5M |
| ZLAB Zai Lab Limited Unsponsored ADR compare | −$159.2M |
| PHVS Pharvaris N.V. compare | −$178.0M |
| XNCR Xencor, Inc. | −$205.8M |
| RXRX Recursion Pharmaceuticals, Inc. compare | −$310.5M |
| BEAM Beam Therapeutics Inc. compare | −$388.6M |
| RCUS Arcus Biosciences, Inc. compare | −$465.0M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on XNCR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement